ASST Spedali Civili - S.C. Ematologia Trials

ASST Spedali Civili - S.C. Ematologia	Welcome, Profile Billing Logout

57 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Gini, Guido

FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting

430

Europe

Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses

Fondazione Italiana Linfomi ONLUS, GRADE Onlus

Diffuse Large B-Cell Lymphoma, Elderly Patients

09/25

09/30

NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting

2/3

501

Europe, US, RoW

Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)

Karyopharm Therapeutics Inc

Relapsed/refractory Diffuse Large B-cell Lymphoma

12/25

RAFTING, NCT04866654 / 2020-002382-33: Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Recruiting

160

Europe

Nivolumab 10 MG/ML

Medical University of Gdansk, Medical Research Agency

Hodgkin Lymphoma

09/22

07/26

NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting

Europe

Ibrutinib, IMBRUVICA (commercial name)

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

DLBCL

07/24

07/27

FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated

Europe

Copanlisib, ALIQOPA

Fondazione Italiana Linfomi - ETS

Diffuse Large B-cell Lymphoma

12/24

CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting

Europe

Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

Plasmablastic Lymphoma

01/25

MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting

175

Europe

Ibrutinib, Rituximab

International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV

Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma

06/27

FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting

Europe

Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

09/28

09/33

FIL_RICCO, NCT06835530: A Combination of Rituximab and CC-99282 As Front-line Therapy for Older Frail Patients with Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated with a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Not yet recruiting

Europe

Rituximab + Golcadomide (CC-99282)

Fondazione Italiana Linfomi - ETS

Diffuse Large B Cell Non-Hodgkin Lymphoma

04/30

FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn

150

Europe

R-DHAP, Pola-R-DHAP

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent

01/29

NCT02916316: Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell

Active, not recruiting

N/A

127

Europe

R-CHOP with doxorubicin, R-CHOP with doxorubicin analogue, R-COMP

Fondazione Italiana Linfomi - ETS

Lymphoma, Large B-Cell, Diffuse Large B-Cell

12/20

12/24

NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Mantle Cell Lymphoma

03/25

NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting

N/A

200

Europe

Incyte Biosciences Italy S.r.l, Advice Pharma Group srl

DLBCL - Diffuse Large B Cell Lymphoma

06/25

06/27

NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting

N/A

130

Europe

Chimeric Antigen Receptor T-cells (CAR-T) therapy

Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company

Non-hodgkin Lymphoma,B Cell

07/26

NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting

N/A

125

Europe

Zanubrutinib

Fondazione Italiana Linfomi - ETS

Waldenström's Macroglobulinemia (WM)

07/26

FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Not yet recruiting

N/A

200

Europe

Fondazione Italiana Linfomi - ETS

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

12/27

NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting

N/A

150

Europe

Fondazione Italiana Linfomi - ETS

Low Grade Non-Hodgkin's Lymphoma, Adult

02/25

NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting

N/A

400

Europe

Treatment for clinical practise

Fondazione Italiana Linfomi ONLUS

Classical Hodgkin Lymphoma

01/26

NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting

N/A

552

Europe

Lifestyles Implemented-Survivorship Care Plan (LS-SCP)

Fondazione Italiana Linfomi - ETS

Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)

02/26

FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

Arcaini, Luca

TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL

Recruiting

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL

Active, not recruiting

241

Europe, Canada, US, RoW

Brentuximab vedotin, Rituximab, Lenalidomide, Placebo

Seagen, a wholly owned subsidiary of Pfizer

Diffuse Large B-cell Lymphoma

11/25

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting

430

Europe

Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses

Fondazione Italiana Linfomi ONLUS, GRADE Onlus

Diffuse Large B-Cell Lymphoma, Elderly Patients

09/25

09/30

FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting

602

Europe

Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

07/28

07/30

RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting

120

Europe

Rituximab, Truxima, Zanubrutinib, Brukinsa

International Extranodal Lymphoma Study Group (IELSG)

Splenic Marginal Zone Lymphoma

05/29

CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting

504

Europe, Canada, US, RoW

Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone

Acrotech Biopharma Inc.

Peripheral T Cell Lymphoma

07/30

11/30

FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting

190

Europe

Radiotherapy, Radiotherapy plus Obinutuzumab

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Follicular Lymphoma

04/31

BArT, NCT02836925 / 2015-004830-81: Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

Completed

Europe

Ledipasvir+Sofosbuvir, Harvoni, Sofosbuvir+Velpatasvir, Epclusa

Fondazione Italiana Linfomi ONLUS

Indolent B-cell Lymphoma, Hepatitis C

02/20

11/22

NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting

Europe

Ibrutinib, IMBRUVICA (commercial name)

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

DLBCL

07/24

07/27

FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated

Europe

Copanlisib, ALIQOPA

Fondazione Italiana Linfomi - ETS

Diffuse Large B-cell Lymphoma

12/24

SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting

Europe, US, RoW

brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone

Seagen, a wholly owned subsidiary of Pfizer

Peripheral T-cell Lymphoma

05/24

12/25

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting

Europe

Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

Plasmablastic Lymphoma

01/25

MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting

175

Europe

Ibrutinib, Rituximab

International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV

Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma

06/27

FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting

Europe

Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)

Fondazione Italiana Linfomi - ETS

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma

04/26

04/29

SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting

1/2

Europe, US

EO2463, lenalidomide, Revlimid, rituximab, MabThera

Enterome

Follicular Lymphoma, Marginal Zone Lymphoma

05/26

05/32

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Castleman Disease

01/25

ProDigALIty, NCT06383143: Promoting Diagnosis and Management of AL in Italy

Recruiting

N/A

760

Europe

no intervention

Fondazione IRCCS Policlinico San Matteo di Pavia

AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

05/25

PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Recruiting

N/A

350

Europe

International Extranodal Lymphoma Study Group (IELSG)

Marginal Zone Lymphoma

12/25

NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Mantle Cell Lymphoma

03/25

FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting

N/A

654

Europe

EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

06/25

06/26

FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting

N/A

400

Europe

Fondazione Italiana Linfomi - ETS, Takeda

Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome

07/26

INTHEMA, NCT04298892: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies

Recruiting

N/A

2000

Europe

clinical data and sample collection

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Azienda Unità Sanitaria Locale della Romagna

Haematologic Disease, Haematological Malignancy

02/25

FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting

N/A

150

Europe

Fondazione Italiana Linfomi - ETS

Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome

05/25

07/25

NCT06712459: Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Not yet recruiting

N/A

100

Europe, US

International Extranodal Lymphoma Study Group (IELSG)

Transformed Splenic Marginal Zone Lymphoma

03/29

FIL_FollVax22, NCT06070961: Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

Recruiting

N/A

Europe

Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus, Humoral immunity vs Varicella Zoster Virus, Diphtheria toxin-binding IgG, Tetanus toxoid-binding IgG, T-cell populations and markers characterization

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

05/27

FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting

N/A

300

Europe, US, RoW

International Extranodal Lymphoma Study Group (IELSG)

Nodal Marginal Zone Lymphoma

12/26

Anastasia, Antonella

RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting

128

Europe

R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)

Fondazione Italiana Linfomi - ETS

Lymphoma, Follicular

01/23

08/27

RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting

120

Europe

Rituximab, Truxima, Zanubrutinib, Brukinsa

International Extranodal Lymphoma Study Group (IELSG)

Splenic Marginal Zone Lymphoma

05/29

FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting

190

Europe

Radiotherapy, Radiotherapy plus Obinutuzumab

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Follicular Lymphoma

04/31

FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting

Europe

Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

09/28

09/33

FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting

N/A

654

Europe

EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

06/25

06/26

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

05/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Gini, Guido

FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting

430

Europe

Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses

Fondazione Italiana Linfomi ONLUS, GRADE Onlus

Diffuse Large B-Cell Lymphoma, Elderly Patients

09/25

09/30

NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting

2/3

501

Europe, US, RoW

Karyopharm Therapeutics Inc

Relapsed/refractory Diffuse Large B-cell Lymphoma

12/25

RAFTING, NCT04866654 / 2020-002382-33: Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Recruiting

160

Europe

Nivolumab 10 MG/ML

Medical University of Gdansk, Medical Research Agency

Hodgkin Lymphoma

09/22

07/26

NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting

Europe

Ibrutinib, IMBRUVICA (commercial name)

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

DLBCL

07/24

07/27

FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated

Europe

Copanlisib, ALIQOPA

Fondazione Italiana Linfomi - ETS

Diffuse Large B-cell Lymphoma

12/24

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting

Europe

Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

Plasmablastic Lymphoma

01/25

MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting

175

Europe

Ibrutinib, Rituximab

International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV

Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma

06/27

FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting

Europe

Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

09/28

09/33

Not yet recruiting

Europe

Rituximab + Golcadomide (CC-99282)

Fondazione Italiana Linfomi - ETS

Diffuse Large B Cell Non-Hodgkin Lymphoma

04/30

FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn

150

Europe

R-DHAP, Pola-R-DHAP

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent

01/29

NCT02916316: Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell

Active, not recruiting

N/A

127

Europe

R-CHOP with doxorubicin, R-CHOP with doxorubicin analogue, R-COMP

Fondazione Italiana Linfomi - ETS

Lymphoma, Large B-Cell, Diffuse Large B-Cell

12/20

12/24

NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Mantle Cell Lymphoma

03/25

Recruiting

N/A

200

Europe

Incyte Biosciences Italy S.r.l, Advice Pharma Group srl

DLBCL - Diffuse Large B Cell Lymphoma

06/25

06/27

NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting

N/A

130

Europe

Chimeric Antigen Receptor T-cells (CAR-T) therapy

Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company

Non-hodgkin Lymphoma,B Cell

07/26

Not yet recruiting

N/A

125

Europe

Zanubrutinib

Fondazione Italiana Linfomi - ETS

Waldenström's Macroglobulinemia (WM)

07/26

FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Not yet recruiting

N/A

200

Europe

Fondazione Italiana Linfomi - ETS

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

12/27

NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting

N/A

150

Europe

Fondazione Italiana Linfomi - ETS

Low Grade Non-Hodgkin's Lymphoma, Adult

02/25

NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting

N/A

400

Europe

Treatment for clinical practise

Fondazione Italiana Linfomi ONLUS

Classical Hodgkin Lymphoma

01/26

NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting

N/A

552

Europe

Lifestyles Implemented-Survivorship Care Plan (LS-SCP)

Fondazione Italiana Linfomi - ETS

Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)

02/26

FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

Arcaini, Luca

TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL

Recruiting

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL

Active, not recruiting

241

Europe, Canada, US, RoW

Brentuximab vedotin, Rituximab, Lenalidomide, Placebo

Seagen, a wholly owned subsidiary of Pfizer

Diffuse Large B-cell Lymphoma

11/25

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting

430

Europe

Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses

Fondazione Italiana Linfomi ONLUS, GRADE Onlus

Diffuse Large B-Cell Lymphoma, Elderly Patients

09/25

09/30

FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting

602

Europe

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

07/28

07/30

RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting

120

Europe

Rituximab, Truxima, Zanubrutinib, Brukinsa

International Extranodal Lymphoma Study Group (IELSG)

Splenic Marginal Zone Lymphoma

05/29

CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting

504

Europe, Canada, US, RoW

Acrotech Biopharma Inc.

Peripheral T Cell Lymphoma

07/30

11/30

FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting

190

Europe

Radiotherapy, Radiotherapy plus Obinutuzumab

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Follicular Lymphoma

04/31

BArT, NCT02836925 / 2015-004830-81: Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

Completed

Europe

Ledipasvir+Sofosbuvir, Harvoni, Sofosbuvir+Velpatasvir, Epclusa

Fondazione Italiana Linfomi ONLUS

Indolent B-cell Lymphoma, Hepatitis C

02/20

11/22

NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting

Europe

Ibrutinib, IMBRUVICA (commercial name)

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

DLBCL

07/24

07/27

FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated

Europe

Copanlisib, ALIQOPA

Fondazione Italiana Linfomi - ETS

Diffuse Large B-cell Lymphoma

12/24

SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting

Europe, US, RoW

brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone

Seagen, a wholly owned subsidiary of Pfizer

Peripheral T-cell Lymphoma

05/24

12/25

Terminated

Europe

Rituximab, Chemotherapy, Tenofovir alafenamide

Gruppo Italiano Malattie EMatologiche dell'Adulto

Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia

05/24

FIL_DALYA, NCT04915248 / 2020-000409-94: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Recruiting

Europe

Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

Plasmablastic Lymphoma

01/25

MALIBU, NCT03697512 / 2018-002364-44: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Active, not recruiting

175

Europe

Ibrutinib, Rituximab

International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV

Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma

06/27

FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting

Europe

Fondazione Italiana Linfomi - ETS

Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma

04/26

04/29

SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting

1/2

Europe, US

EO2463, lenalidomide, Revlimid, rituximab, MabThera

Enterome

Follicular Lymphoma, Marginal Zone Lymphoma

05/26

05/32

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

Recruiting

N/A

Europe

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Castleman Disease

01/25

ProDigALIty, NCT06383143: Promoting Diagnosis and Management of AL in Italy

Recruiting

N/A

760

Europe

no intervention

Fondazione IRCCS Policlinico San Matteo di Pavia

AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

05/25

PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Recruiting

N/A

350

Europe

International Extranodal Lymphoma Study Group (IELSG)

Marginal Zone Lymphoma

12/25

NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Mantle Cell Lymphoma

03/25

FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting

N/A

654

Europe

EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

06/25

06/26

FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting

N/A

400

Europe

Fondazione Italiana Linfomi - ETS, Takeda

Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome

07/26

INTHEMA, NCT04298892: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies

Recruiting

N/A

2000

Europe

clinical data and sample collection

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Azienda Unità Sanitaria Locale della Romagna

Haematologic Disease, Haematological Malignancy

02/25

FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting

N/A

150

Europe

Fondazione Italiana Linfomi - ETS

Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome

05/25

07/25

NCT06712459: Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Not yet recruiting

N/A

100

Europe, US

International Extranodal Lymphoma Study Group (IELSG)

Transformed Splenic Marginal Zone Lymphoma

03/29

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

05/27

FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting

N/A

1500

Europe

"novel" MAB (alone or in combination)

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Non-Hodgkin Lymphoma, B-cell

10/38

NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting

N/A

300

Europe, US, RoW

International Extranodal Lymphoma Study Group (IELSG)

Nodal Marginal Zone Lymphoma

12/26

Anastasia, Antonella

RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting

128

Europe

R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)

Fondazione Italiana Linfomi - ETS

Lymphoma, Follicular

01/23

08/27

RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting

120

Europe

Rituximab, Truxima, Zanubrutinib, Brukinsa

International Extranodal Lymphoma Study Group (IELSG)

Splenic Marginal Zone Lymphoma

05/29

FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting

190

Europe

Radiotherapy, Radiotherapy plus Obinutuzumab

Fondazione Italiana Linfomi - ETS, Roche Pharma AG

Follicular Lymphoma

04/31

FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting

Europe

Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

09/28

09/33

FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting

N/A

654

Europe

EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

06/25

06/26

Recruiting

N/A

Europe

Fondazione Italiana Linfomi - ETS

Follicular Lymphoma

05/27

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites